• Entecavir in Acute Hepatitis B: What Comparisons Show

  2026-10-17

  A systematic review of five trials found insufficient evidence that nucleoside analogues improved virological cure or HBsAg clearance over standard care in severe acute hepatitis B. Entecavir appeared favorable to lamivudine in one small direct comparison, but that result did not establish superiority over standard care or predict outcomes in chronic HBV infection.

• Toremifene: Product Identity and Evidence Boundaries

  2026-10-16

  A source-limited overview of Toremifene as a selective estrogen-receptor modulator, distinguishing the APExBIO product description, its reported in vitro growth-inhibition value, and claims about xenograft research from independently established evidence.

• TROLL-8 mRNA: Evidence and Scope

  2026-10-16

  The listed product information identifies TROLL-8 mRNA (SKU R1999) as an APExBIO product, but provides no description, molecular characterization, mechanism, application, or identity-matched research paper. The name alone does not establish sequence, encoded product, formulation, biological activity, or intended use. Accordingly, no product-specific performance, mechanism, safety, or comparative claim can be supported.

• Annexin V-PE Apoptosis Kit: Evidence and Scope

  2026-10-15

  The APExBIO Annexin V-PE Apoptosis Kit, SKU K2281, is documented as a fluorescence-based research assay for Annexin V binding to cell-surface phosphatidylserine. Its readout is relevant to an apoptosis-associated, often early phenotype, but the supplied product information and related summaries do not establish apoptosis specificity, quantitative performance, comparative validity, or clinical utility.

• BMS 599626: Documented EGFR/HER2 Scope

  2026-10-15

  BMS 599626 dihydrochloride is described by APExBIO as an EGFR and ErbB2 inhibitor with reported activity against HER4 at a higher concentration range. The product page supports a mechanistic framework involving receptor phosphorylation, HER1/HER2 heterodimerization, downstream signaling, and tumor-growth readouts, but it is not a matched primary research paper and does not establish independent efficacy, broad selectivity, or clinical relevance.

• Sulfo-NHS-SS-Biotin: Mechanism and Evidence

  2026-10-14

  The APExBIO product description identifies Sulfo-NHS-SS-Biotin, also called sulfosuccinimidyl-20(biotinamido)ethyl-1,3-dithiopropionate, as a water-soluble, primary-amine-reactive biotinylation reagent with a disulfide-cleavable spacer. Its documented scope includes protein and antibody labeling, affinity capture, detection, and conceptual cell-surface applications, but no identity-matched research study or comparative performance data were supplied.

• Neddylation, RIPK3 Degradation, and Viral Inflammation

  2026-10-14

  A primary Immunity study links an orthopoxvirus protein to SCF-dependent RIPK3 degradation, necroptosis suppression, and altered inflammation. MLN4924 HCl salt provides a conceptual pharmacological entry point for studying NEDD8-activating enzyme and cullin-RING ligase biology, but the supplied study does not establish that this compound was used or that NAE inhibition reproduces viral protein loss.

• Erastin and Ferroptosis: Evidence and Boundaries

  2026-10-13

  Erastin is a research tool for studying ferroptosis and oxidative cell death, but the supplied renal-injury study supports a context-specific mechanistic interpretation rather than broad claims about cancer selectivity, clinical treatment, or supplier-specific performance.

• What iTBS Findings in SCA3 Mice Show

  2026-10-12

  A recent mouse study reports that intermittent theta-burst stimulation improved motor coordination and altered cerebellar markers linked to ataxin-3 aggregation, neuroinflammation, and autophagy. The findings are mechanistically suggestive but remain preliminary: the work was conducted in a transgenic mouse model, used a small sample, and did not establish long-term disease modification or relevance to people with SCA3.

• Erastin, Ferroptosis, and ROS: Evidence Boundaries

  2026-10-12

  Erastin is commonly described as a ferroptosis inducer, but the supplied evidence does not connect it directly to the reported carrier-platin study. Liu et al. describe a distinct, preclinical platinum-based approach to rapid ROS-associated cancer-cell death, while important questions remain about mechanism, selectivity, reproducibility, and clinical relevance.

• Erastin Beyond the Benchmark: Ferroptosis to Translation

  2026-10-11

  Erastin is more than a ferroptosis inducer: it is a mechanistic lens for studying redox vulnerability, tumor heterogeneity, and the immune consequences of oxidative cell death. This analysis connects preclinical evidence with translational questions without overstating clinical readiness.

• Erastin and Ferroptosis: Evidence, Scope, and Limits

  2026-10-10

  A source-grounded overview of Erastin as a ferroptosis inducer, explaining ferroptosis principles, the strength of available evidence, interpretation of HCC findings, and the boundaries of conclusions from cell and database studies.

• Bafilomycin C1 in Lysosomal and Cardiac Research

  2026-10-09

  Bafilomycin C1 is commonly described as a vacuolar H+-ATPases inhibitor for studying lysosomal acidification, autophagy, and intracellular trafficking. This overview separates supplier information from peer-reviewed evidence and examines how lysosomal perturbation could be interpreted in high-content cardiotoxicity research without treating indirect findings as proof of compound-specific effects.

• RNA Pol II Inhibition and Active Cell Death Signaling

  2026-10-09

  Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active signaling rather than passive loss of transcription-dependent gene products. The study identifies loss of hypophosphorylated RNA Pol IIA and defines a Pol II degradation-dependent apoptotic response, providing a framework for interpreting transcription-targeting therapies in cancer research.

• From Surface Labeling to Spatial Proteome Maps

  2026-10-08

  Spatial proteomics is moving beyond isolated markers toward cell-type-resolved molecular maps of intact tissue. This thought-leadership article examines how membrane-restricted tyramide chemistry can support that transition, what the 2025 PSPro study demonstrates, and where Biotin-XX Tyramide Reagent fits—without confusing conceptual relevance with direct validation.

8081 records 1/539 page Next 12345 下5页 Last page